Jaguar health signs definitive agreement for $5 million non-dilutive financing transaction involving sale of royalty rights related to future potential crofelemer (mytesi) covid-related indication revenue stream

No royalty payments due for 36 months company has started to identify key opinion leader physicians in the us as well as europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of covid-19 survivors for an extended period after recovery san francisco, ca / accesswire / march 9, 2021 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that the company has signed the definitive agreement (the "agreement") related to the previously announced term sheet for a third non-dilutive royalty financing transaction, pursuant to which jaguar is selling to the lender for an aggregate purchase price of $5 million (the "royalty purchase price") a royalty interest in future potential crofelemer (mytesi®) sales for the proposed covid-related indication in long-hauler patients (as defined below), for which the company is currently exploring the pathway of conditional marketing authorization in the european union. the covid-related indication is the initial indication to be pursued by napo eu, the exclusive target of the planned dragon special purpose acquisition company (the "dragon spac"), which is anticipated to be listed on aim italia.
JAGX Ratings Summary
JAGX Quant Ranking